Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

PLOS Medicine logoLink to PLOS Medicine
. 2004 Dec 28;1(3):e73. doi: 10.1371/journal.pmed.0010073

Correction: Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1

PMCID: PMC539057

Published October 19, 2004

In PLoS Medicine, volume 1, issue 1:

Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1

Frank van Leth, Prahpan Phanuphak, Erik Stroes, Brian Gazzard, Pedro Cahn, et al.

DOI: 10.1371/journal.pmed.0010019

The following information was missing from the legend for Figure 1: closed squares, NVP; open squares, EFV; error bars denote standard errors. Oliver Flint at Bristol-Myers Squibb alerted PLoS Medicine to this omission.

Figure 1. Change in Plasma Concentrations of Lipids and Lipoproteins.

Figure 1

Adjusted for sex, region, pVL decrease, and CD4+-cell increase. Closed squares, NVP; open squares, EFV; error bars denote standard errors.

There was also a line with open circles in Figure 1F that should not have been included.

Footnotes

Citation: (2004) Correction: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 1(1): e19.


Articles from PLoS Medicine are provided here courtesy of PLOS

RESOURCES